Pilot Study of the Effects of Intermittent Interleukin-2 on Human Immunodeficiency Virus (HIV)–Specific Immune Responses in Patients Treated during Recently Acquired HIV Infection
Highly active antiretroviral therapy (HAART) initiated during acute human immunodeficiency virus (HIV) infection may preserve HIV-specific CD4+ T cell responses that are thought to enhance HIV-specific CD8+ T cell function. The present pilot study was designed to determine whether preserved HIV-spec...
Gespeichert in:
| Veröffentlicht in: | The Journal of infectious diseases 2002-01, Vol.185 (1), p.61-8 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 8 |
|---|---|
| container_issue | 1 |
| container_start_page | 61 |
| container_title | The Journal of infectious diseases |
| container_volume | 185 |
| creator | Dybul, Mark Hidalgo, Bertha Chun, Tae-Wook Belson, Michael Migueles, Stephen A. Justement, Jesse S. Herpin, Betsey Perry, Cheryl Hallahan, Claire W. Davey, Richard T. Metcalf, Julia A. Connors, Mark Fauci, Anthony S. |
| description | Highly active antiretroviral therapy (HAART) initiated during acute human immunodeficiency virus (HIV) infection may preserve HIV-specific CD4+ T cell responses that are thought to enhance HIV-specific CD8+ T cell function. The present pilot study was designed to determine whether preserved HIV-specific immune responses are augmented by the administration of the immunomodulatory agent interleukin (IL)–2. Nine persons recently ( |
| doi_str_mv | 10.1086/338123 |
| format | Article |
| fullrecord | <record><control><sourceid>jstor_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_18284299</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><jstor_id>30138126</jstor_id><oup_id>10.1086/338123</oup_id><sourcerecordid>30138126</sourcerecordid><originalsourceid>FETCH-LOGICAL-c481t-415b3a7021963ed0dcb4a9ff11335ec0a462f07542871a649328ee23f29eb0483</originalsourceid><addsrcrecordid>eNp1kd9q1EAUxoModq36BsooKHoRnT_JZHJZSusuLVi6axFvwuzkRGebzKTzB9w738Fn8YV8EmfJ0org1XDm-53vfPBl2VOC3xEs-HvGBKHsXjYjJatyzgm7n80wpjQnoq4PskfebzDGBePVw-yAkKrktaCz7NeF7m1AyxDbLbIdCt8AnXQdqOB348IEcIMOAUyYhh7itTY5RdageRykQYthiMa20GmlwagtutIuevRmvrh6-_vHz-UISidt4gBdgh-t8eCRNuhChrSTbq0cyAAtaqPT5muCVPrut-hI3UTtkpDcUoBdMG3N4-xBJ3sPT_bvYfbp9GR1PM_PP35YHB-d56oQJOQFKddMVpiSmjNocavWhay7jhDGSlBYFpx2uCoLKioieVEzKgAo62gNa1wIdpi9nnxHZ28i-NAM2ivoe2nARt8QQUVB6zqBL_8BNzY6k7I1lDJR84r85aac9d5B14xOD9JtG4KbXYvN1GICn-_d4nqA9g7b15aAV3tAeiX7zkmjtL_jWEEJr8vEvZg4G8f_H3s2MRsfrLulGCY7nSc9n3TtA3y_1aW7bnjFqrKZf_7SXK5OzwRmy-aM_QFXzsf7</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>223896718</pqid></control><display><type>article</type><title>Pilot Study of the Effects of Intermittent Interleukin-2 on Human Immunodeficiency Virus (HIV)–Specific Immune Responses in Patients Treated during Recently Acquired HIV Infection</title><source>MEDLINE</source><source>Jstor Complete Legacy</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>Alma/SFX Local Collection</source><creator>Dybul, Mark ; Hidalgo, Bertha ; Chun, Tae-Wook ; Belson, Michael ; Migueles, Stephen A. ; Justement, Jesse S. ; Herpin, Betsey ; Perry, Cheryl ; Hallahan, Claire W. ; Davey, Richard T. ; Metcalf, Julia A. ; Connors, Mark ; Fauci, Anthony S.</creator><creatorcontrib>Dybul, Mark ; Hidalgo, Bertha ; Chun, Tae-Wook ; Belson, Michael ; Migueles, Stephen A. ; Justement, Jesse S. ; Herpin, Betsey ; Perry, Cheryl ; Hallahan, Claire W. ; Davey, Richard T. ; Metcalf, Julia A. ; Connors, Mark ; Fauci, Anthony S.</creatorcontrib><description>Highly active antiretroviral therapy (HAART) initiated during acute human immunodeficiency virus (HIV) infection may preserve HIV-specific CD4+ T cell responses that are thought to enhance HIV-specific CD8+ T cell function. The present pilot study was designed to determine whether preserved HIV-specific immune responses are augmented by the administration of the immunomodulatory agent interleukin (IL)–2. Nine persons recently (<6 months) infected with HIV were randomized to receive HAART alone or HAART plus 3 cycles of intermittent IL-2 during a 12-month period. Although HAART plus IL-2 significantly increased counts of total and naive CD4+ T cells, compared with HAART alone, there was no increase in CD4+ or CD8+ HIV-specific immune responses. In addition, adjuvant IL-2 therapy did not reduce the pool of HIV-infected resting CD4+ T cells. Thus, although intermittent IL-2 plus HAART quantitatively increased CD4+ T cells, this increase was not selective for HIV-specific CD4+ or CD8+ T cell responses in recently infected persons</description><identifier>ISSN: 0022-1899</identifier><identifier>EISSN: 1537-6613</identifier><identifier>DOI: 10.1086/338123</identifier><identifier>PMID: 11756982</identifier><identifier>CODEN: JIDIAQ</identifier><language>eng</language><publisher>Chicago, IL: The University of Chicago Press</publisher><subject>AIDS ; Anti-HIV Agents - therapeutic use ; Antigens ; Antiretroviral Therapy, Highly Active ; B lymphocytes ; Benzoxazines ; Biological and medical sciences ; CD4 antigen ; CD4-Positive T-Lymphocytes - immunology ; CD8 antigen ; CD8-Positive T-Lymphocytes - immunology ; Coculture Techniques ; Drug Synergism ; Highly active antiretroviral therapy ; HIV ; HIV 1 ; HIV infections ; HIV Infections - drug therapy ; HIV Infections - immunology ; HIV Protease Inhibitors - therapeutic use ; Human immunodeficiency virus ; Human viral diseases ; Humans ; Indinavir - therapeutic use ; Infections ; Infectious diseases ; Interferon-gamma - biosynthesis ; Interleukin-2 - administration & dosage ; Interleukin-2 - therapeutic use ; Lamivudine - therapeutic use ; Lymphocyte Activation ; Lymphocyte Subsets ; Major Articles ; Medical sciences ; Oxazines - therapeutic use ; Pilot Projects ; Reverse Transcriptase Inhibitors - therapeutic use ; Stavudine - therapeutic use ; T lymphocytes ; Viral diseases ; Viral diseases of the lymphoid tissue and the blood. Aids ; Viruses</subject><ispartof>The Journal of infectious diseases, 2002-01, Vol.185 (1), p.61-8</ispartof><rights>Copyright 2002 Infectious Diseases Society of America</rights><rights>2002 by the Infectious Diseases Society of America 2002</rights><rights>2002 INIST-CNRS</rights><rights>Copyright University of Chicago, acting through its Press Jan 1, 2002</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c481t-415b3a7021963ed0dcb4a9ff11335ec0a462f07542871a649328ee23f29eb0483</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.jstor.org/stable/pdf/30138126$$EPDF$$P50$$Gjstor$$H</linktopdf><linktohtml>$$Uhttps://www.jstor.org/stable/30138126$$EHTML$$P50$$Gjstor$$H</linktohtml><link.rule.ids>314,780,784,803,4014,27914,27915,27916,58008,58241</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=13421695$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11756982$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Dybul, Mark</creatorcontrib><creatorcontrib>Hidalgo, Bertha</creatorcontrib><creatorcontrib>Chun, Tae-Wook</creatorcontrib><creatorcontrib>Belson, Michael</creatorcontrib><creatorcontrib>Migueles, Stephen A.</creatorcontrib><creatorcontrib>Justement, Jesse S.</creatorcontrib><creatorcontrib>Herpin, Betsey</creatorcontrib><creatorcontrib>Perry, Cheryl</creatorcontrib><creatorcontrib>Hallahan, Claire W.</creatorcontrib><creatorcontrib>Davey, Richard T.</creatorcontrib><creatorcontrib>Metcalf, Julia A.</creatorcontrib><creatorcontrib>Connors, Mark</creatorcontrib><creatorcontrib>Fauci, Anthony S.</creatorcontrib><title>Pilot Study of the Effects of Intermittent Interleukin-2 on Human Immunodeficiency Virus (HIV)–Specific Immune Responses in Patients Treated during Recently Acquired HIV Infection</title><title>The Journal of infectious diseases</title><addtitle>The Journal of Infectious Diseases</addtitle><addtitle>The Journal of Infectious Diseases</addtitle><description>Highly active antiretroviral therapy (HAART) initiated during acute human immunodeficiency virus (HIV) infection may preserve HIV-specific CD4+ T cell responses that are thought to enhance HIV-specific CD8+ T cell function. The present pilot study was designed to determine whether preserved HIV-specific immune responses are augmented by the administration of the immunomodulatory agent interleukin (IL)–2. Nine persons recently (<6 months) infected with HIV were randomized to receive HAART alone or HAART plus 3 cycles of intermittent IL-2 during a 12-month period. Although HAART plus IL-2 significantly increased counts of total and naive CD4+ T cells, compared with HAART alone, there was no increase in CD4+ or CD8+ HIV-specific immune responses. In addition, adjuvant IL-2 therapy did not reduce the pool of HIV-infected resting CD4+ T cells. Thus, although intermittent IL-2 plus HAART quantitatively increased CD4+ T cells, this increase was not selective for HIV-specific CD4+ or CD8+ T cell responses in recently infected persons</description><subject>AIDS</subject><subject>Anti-HIV Agents - therapeutic use</subject><subject>Antigens</subject><subject>Antiretroviral Therapy, Highly Active</subject><subject>B lymphocytes</subject><subject>Benzoxazines</subject><subject>Biological and medical sciences</subject><subject>CD4 antigen</subject><subject>CD4-Positive T-Lymphocytes - immunology</subject><subject>CD8 antigen</subject><subject>CD8-Positive T-Lymphocytes - immunology</subject><subject>Coculture Techniques</subject><subject>Drug Synergism</subject><subject>Highly active antiretroviral therapy</subject><subject>HIV</subject><subject>HIV 1</subject><subject>HIV infections</subject><subject>HIV Infections - drug therapy</subject><subject>HIV Infections - immunology</subject><subject>HIV Protease Inhibitors - therapeutic use</subject><subject>Human immunodeficiency virus</subject><subject>Human viral diseases</subject><subject>Humans</subject><subject>Indinavir - therapeutic use</subject><subject>Infections</subject><subject>Infectious diseases</subject><subject>Interferon-gamma - biosynthesis</subject><subject>Interleukin-2 - administration & dosage</subject><subject>Interleukin-2 - therapeutic use</subject><subject>Lamivudine - therapeutic use</subject><subject>Lymphocyte Activation</subject><subject>Lymphocyte Subsets</subject><subject>Major Articles</subject><subject>Medical sciences</subject><subject>Oxazines - therapeutic use</subject><subject>Pilot Projects</subject><subject>Reverse Transcriptase Inhibitors - therapeutic use</subject><subject>Stavudine - therapeutic use</subject><subject>T lymphocytes</subject><subject>Viral diseases</subject><subject>Viral diseases of the lymphoid tissue and the blood. Aids</subject><subject>Viruses</subject><issn>0022-1899</issn><issn>1537-6613</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kd9q1EAUxoModq36BsooKHoRnT_JZHJZSusuLVi6axFvwuzkRGebzKTzB9w738Fn8YV8EmfJ0org1XDm-53vfPBl2VOC3xEs-HvGBKHsXjYjJatyzgm7n80wpjQnoq4PskfebzDGBePVw-yAkKrktaCz7NeF7m1AyxDbLbIdCt8AnXQdqOB348IEcIMOAUyYhh7itTY5RdageRykQYthiMa20GmlwagtutIuevRmvrh6-_vHz-UISidt4gBdgh-t8eCRNuhChrSTbq0cyAAtaqPT5muCVPrut-hI3UTtkpDcUoBdMG3N4-xBJ3sPT_bvYfbp9GR1PM_PP35YHB-d56oQJOQFKddMVpiSmjNocavWhay7jhDGSlBYFpx2uCoLKioieVEzKgAo62gNa1wIdpi9nnxHZ28i-NAM2ivoe2nARt8QQUVB6zqBL_8BNzY6k7I1lDJR84r85aac9d5B14xOD9JtG4KbXYvN1GICn-_d4nqA9g7b15aAV3tAeiX7zkmjtL_jWEEJr8vEvZg4G8f_H3s2MRsfrLulGCY7nSc9n3TtA3y_1aW7bnjFqrKZf_7SXK5OzwRmy-aM_QFXzsf7</recordid><startdate>20020101</startdate><enddate>20020101</enddate><creator>Dybul, Mark</creator><creator>Hidalgo, Bertha</creator><creator>Chun, Tae-Wook</creator><creator>Belson, Michael</creator><creator>Migueles, Stephen A.</creator><creator>Justement, Jesse S.</creator><creator>Herpin, Betsey</creator><creator>Perry, Cheryl</creator><creator>Hallahan, Claire W.</creator><creator>Davey, Richard T.</creator><creator>Metcalf, Julia A.</creator><creator>Connors, Mark</creator><creator>Fauci, Anthony S.</creator><general>The University of Chicago Press</general><general>University of Chicago Press</general><general>Oxford University Press</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7U9</scope><scope>H94</scope></search><sort><creationdate>20020101</creationdate><title>Pilot Study of the Effects of Intermittent Interleukin-2 on Human Immunodeficiency Virus (HIV)–Specific Immune Responses in Patients Treated during Recently Acquired HIV Infection</title><author>Dybul, Mark ; Hidalgo, Bertha ; Chun, Tae-Wook ; Belson, Michael ; Migueles, Stephen A. ; Justement, Jesse S. ; Herpin, Betsey ; Perry, Cheryl ; Hallahan, Claire W. ; Davey, Richard T. ; Metcalf, Julia A. ; Connors, Mark ; Fauci, Anthony S.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c481t-415b3a7021963ed0dcb4a9ff11335ec0a462f07542871a649328ee23f29eb0483</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>AIDS</topic><topic>Anti-HIV Agents - therapeutic use</topic><topic>Antigens</topic><topic>Antiretroviral Therapy, Highly Active</topic><topic>B lymphocytes</topic><topic>Benzoxazines</topic><topic>Biological and medical sciences</topic><topic>CD4 antigen</topic><topic>CD4-Positive T-Lymphocytes - immunology</topic><topic>CD8 antigen</topic><topic>CD8-Positive T-Lymphocytes - immunology</topic><topic>Coculture Techniques</topic><topic>Drug Synergism</topic><topic>Highly active antiretroviral therapy</topic><topic>HIV</topic><topic>HIV 1</topic><topic>HIV infections</topic><topic>HIV Infections - drug therapy</topic><topic>HIV Infections - immunology</topic><topic>HIV Protease Inhibitors - therapeutic use</topic><topic>Human immunodeficiency virus</topic><topic>Human viral diseases</topic><topic>Humans</topic><topic>Indinavir - therapeutic use</topic><topic>Infections</topic><topic>Infectious diseases</topic><topic>Interferon-gamma - biosynthesis</topic><topic>Interleukin-2 - administration & dosage</topic><topic>Interleukin-2 - therapeutic use</topic><topic>Lamivudine - therapeutic use</topic><topic>Lymphocyte Activation</topic><topic>Lymphocyte Subsets</topic><topic>Major Articles</topic><topic>Medical sciences</topic><topic>Oxazines - therapeutic use</topic><topic>Pilot Projects</topic><topic>Reverse Transcriptase Inhibitors - therapeutic use</topic><topic>Stavudine - therapeutic use</topic><topic>T lymphocytes</topic><topic>Viral diseases</topic><topic>Viral diseases of the lymphoid tissue and the blood. Aids</topic><topic>Viruses</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dybul, Mark</creatorcontrib><creatorcontrib>Hidalgo, Bertha</creatorcontrib><creatorcontrib>Chun, Tae-Wook</creatorcontrib><creatorcontrib>Belson, Michael</creatorcontrib><creatorcontrib>Migueles, Stephen A.</creatorcontrib><creatorcontrib>Justement, Jesse S.</creatorcontrib><creatorcontrib>Herpin, Betsey</creatorcontrib><creatorcontrib>Perry, Cheryl</creatorcontrib><creatorcontrib>Hallahan, Claire W.</creatorcontrib><creatorcontrib>Davey, Richard T.</creatorcontrib><creatorcontrib>Metcalf, Julia A.</creatorcontrib><creatorcontrib>Connors, Mark</creatorcontrib><creatorcontrib>Fauci, Anthony S.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>The Journal of infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dybul, Mark</au><au>Hidalgo, Bertha</au><au>Chun, Tae-Wook</au><au>Belson, Michael</au><au>Migueles, Stephen A.</au><au>Justement, Jesse S.</au><au>Herpin, Betsey</au><au>Perry, Cheryl</au><au>Hallahan, Claire W.</au><au>Davey, Richard T.</au><au>Metcalf, Julia A.</au><au>Connors, Mark</au><au>Fauci, Anthony S.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pilot Study of the Effects of Intermittent Interleukin-2 on Human Immunodeficiency Virus (HIV)–Specific Immune Responses in Patients Treated during Recently Acquired HIV Infection</atitle><jtitle>The Journal of infectious diseases</jtitle><stitle>The Journal of Infectious Diseases</stitle><addtitle>The Journal of Infectious Diseases</addtitle><date>2002-01-01</date><risdate>2002</risdate><volume>185</volume><issue>1</issue><spage>61</spage><epage>8</epage><pages>61-8</pages><issn>0022-1899</issn><eissn>1537-6613</eissn><coden>JIDIAQ</coden><abstract>Highly active antiretroviral therapy (HAART) initiated during acute human immunodeficiency virus (HIV) infection may preserve HIV-specific CD4+ T cell responses that are thought to enhance HIV-specific CD8+ T cell function. The present pilot study was designed to determine whether preserved HIV-specific immune responses are augmented by the administration of the immunomodulatory agent interleukin (IL)–2. Nine persons recently (<6 months) infected with HIV were randomized to receive HAART alone or HAART plus 3 cycles of intermittent IL-2 during a 12-month period. Although HAART plus IL-2 significantly increased counts of total and naive CD4+ T cells, compared with HAART alone, there was no increase in CD4+ or CD8+ HIV-specific immune responses. In addition, adjuvant IL-2 therapy did not reduce the pool of HIV-infected resting CD4+ T cells. Thus, although intermittent IL-2 plus HAART quantitatively increased CD4+ T cells, this increase was not selective for HIV-specific CD4+ or CD8+ T cell responses in recently infected persons</abstract><cop>Chicago, IL</cop><pub>The University of Chicago Press</pub><pmid>11756982</pmid><doi>10.1086/338123</doi><tpages>-52</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0022-1899 |
| ispartof | The Journal of infectious diseases, 2002-01, Vol.185 (1), p.61-8 |
| issn | 0022-1899 1537-6613 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_18284299 |
| source | MEDLINE; Jstor Complete Legacy; Oxford University Press Journals All Titles (1996-Current); Alma/SFX Local Collection |
| subjects | AIDS Anti-HIV Agents - therapeutic use Antigens Antiretroviral Therapy, Highly Active B lymphocytes Benzoxazines Biological and medical sciences CD4 antigen CD4-Positive T-Lymphocytes - immunology CD8 antigen CD8-Positive T-Lymphocytes - immunology Coculture Techniques Drug Synergism Highly active antiretroviral therapy HIV HIV 1 HIV infections HIV Infections - drug therapy HIV Infections - immunology HIV Protease Inhibitors - therapeutic use Human immunodeficiency virus Human viral diseases Humans Indinavir - therapeutic use Infections Infectious diseases Interferon-gamma - biosynthesis Interleukin-2 - administration & dosage Interleukin-2 - therapeutic use Lamivudine - therapeutic use Lymphocyte Activation Lymphocyte Subsets Major Articles Medical sciences Oxazines - therapeutic use Pilot Projects Reverse Transcriptase Inhibitors - therapeutic use Stavudine - therapeutic use T lymphocytes Viral diseases Viral diseases of the lymphoid tissue and the blood. Aids Viruses |
| title | Pilot Study of the Effects of Intermittent Interleukin-2 on Human Immunodeficiency Virus (HIV)–Specific Immune Responses in Patients Treated during Recently Acquired HIV Infection |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T05%3A55%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-jstor_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pilot%20Study%20of%20the%20Effects%20of%20Intermittent%20Interleukin-2%20on%20Human%20Immunodeficiency%20Virus%20(HIV)%E2%80%93Specific%20Immune%20Responses%20in%20Patients%20Treated%20during%20Recently%20Acquired%20HIV%20Infection&rft.jtitle=The%20Journal%20of%20infectious%20diseases&rft.au=Dybul,%20Mark&rft.date=2002-01-01&rft.volume=185&rft.issue=1&rft.spage=61&rft.epage=8&rft.pages=61-8&rft.issn=0022-1899&rft.eissn=1537-6613&rft.coden=JIDIAQ&rft_id=info:doi/10.1086/338123&rft_dat=%3Cjstor_proqu%3E30138126%3C/jstor_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=223896718&rft_id=info:pmid/11756982&rft_jstor_id=30138126&rft_oup_id=10.1086/338123&rfr_iscdi=true |